CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $4.99M, lower than 95% of all stocks globally
- PositionDebt-to-equity is 0×, lower than 95% of its Biotechnology peers (median 0.09×)
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
3.69MGBP4.99M · vs all stocks (USD)
Revenue (TTM)
0.00GBPvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
1.52xvs all stocks
52-Week Change
66.47%vs all stocks
Market Capitalization
3.69MGBP4.99M · vs all stocks (USD)
Enterprise Value
3.26MGBP4.40M · vs all stocks (USD)
Price to Book (MRQ)
1.34xvs Biotechnology peers
Enterprise to EBITDA
-5.41xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-27.17%vs Biotechnology peers
Return on Equity (TTM)
-50.94%vs Biotechnology peers
Revenue (TTM)
0.00GBPvs all stocks (USD)
Revenue per Share (TTM)
0.00GBPUpdated Aug 6, 2026Gross Profit (TTM)
0.00GBPvs all stocks (USD)
EBITDA (TTM)
-602.12KGBP-813.18K · vs all stocks (USD)
Net Income (TTM)
-622.50KGBP-840.70K · vs all stocks (USD)
Operating Cash Flow (TTM)
-618.91KGBP-835.86K · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-390.46KGBP-527.33K · vs all stocks (USD)
Trailing Annual Dividend Rate
0.00GBPUpdated Aug 6, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
0.00GBPFY2025 · Sep 30, 2025Cost of Goods Sold
0.00GBPFY2025 · Sep 30, 2025Gross Profit
0.00GBPFY2025 · Sep 30, 2025Operating Income
-660.57KGBP-892.12K · vs all stocks (USD)
Pre-tax Income
-660.57KGBPFY2025 · Sep 30, 2025Income Tax Expense
-7.98KGBPFY2025 · Sep 30, 2025Net Income
-652.59KGBPFY2025 · Sep 30, 2025EBIT
-660.57KGBPFY2025 · Sep 30, 2025EBITDA (Income Statement)
-631.94KGBPFY2025 · Sep 30, 2025Selling, General & Administrative
660.57KGBPFY2025 · Sep 30, 2025EPS (Basic)
-0.0004GBPFY2025 · Sep 30, 2025EPS (Diluted)
-0.0004GBPFY2025 · Sep 30, 2025Basic Shares Outstanding
1.66BSharesFY2025 · Sep 30, 2025Diluted Shares Outstanding
1.66BSharesFY2025 · Sep 30, 2025Net Income from Continuing Operations
-652.59KGBPFY2025 · Sep 30, 2025Preferred Stock Dividends
0.00GBPFY2025 · Sep 30, 2025Operating Cash Flow
-649.77KGBPFY2025 · Sep 30, 2025Cash & Cash Equivalents (End of Period)
97.55KGBPFY2025 · Sep 30, 2025Starting Profit (CF Statement)
-652.59KGBPFY2025 · Sep 30, 2025Stock-based Compensation
0.00GBPFY2025 · Sep 30, 2025Change in Accounts Receivable (CF)
2.81KGBPFY2025 · Sep 30, 2025Net Financing Cash Flow
691.95KGBPFY2025 · Sep 30, 2025Shares Outstanding
2.61BSharesUpdated Aug 6, 2026Float Shares
2.50BSharesUpdated Aug 6, 2026% Held by Insiders
5.37%vs all stocks
% Held by Institutions
0.07%vs all stocks
Total Cash (MRQ)
930.28KGBP1.26M · vs all stocks (USD)
Total Cash per Share (MRQ)
0.00GBPUpdated Aug 6, 2026Total Debt (MRQ)
0.00GBPvs all stocks (USD)
Total Debt to Equity (MRQ)
0.00xvs Biotechnology peers
Current Ratio (MRQ)
4.32xvs Biotechnology peers
Book Value per Share (MRQ)
0.0010GBPUpdated Aug 6, 2026Total Assets
1.02MGBP1.38M · vs all stocks (USD)
Total Current Assets
136.07KGBPFY2025 · Sep 30, 2025Total Liabilities
263.92KGBPFY2025 · Sep 30, 2025Total Non-current Assets
882.78KGBPFY2025 · Sep 30, 2025Total Non-current Liabilities
-2.00GBPFY2025 · Sep 30, 2025Total Current Liabilities
263.92KGBPFY2025 · Sep 30, 2025Cash
97.55KGBPFY2025 · Sep 30, 2025Cash & Cash Equivalents
97.55KGBPFY2025 · Sep 30, 2025Accounts Payable
46.31KGBPFY2025 · Sep 30, 2025Common Stock (Book)
997.86KGBPFY2025 · Sep 30, 2025Retained Earnings
-10.46MGBPFY2025 · Sep 30, 2025Total Shareholders' Equity
754.94KGBP1.02M · vs all stocks (USD)
52-Week Low
0.0720GBXUpdated Aug 6, 202652-Week High
0.5550GBXUpdated Aug 6, 202652-Week Change
66.47%vs all stocks
Beta
1.52xvs all stocks
50-Day MA
0.1750GBXUpdated Aug 6, 2026200-Day MA
0.2254GBXUpdated Aug 6, 2026Avg 10-Day Volume
12.85MSharesUpdated Aug 6, 2026Avg 30-Day Volume
11.04MSharesUpdated Aug 6, 2026Diluted EPS (TTM)
-0.0004GBPUpdated Aug 6, 20262 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Diagnostic
Goodwill-Heavy Equity
Equity looks heavy for the industry, but much of it is goodwill from past acquisitions.
Reads
Where is this company structurally exposed?
Ulcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
It sits well below its peak, and the fall has been both deep and long.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Debt-to-equity is 0×, lower than 95% of its Biotechnology peers (median 0.09×)Notable
Debt-to-equity: 0.00Industry median: 0.09Industry P5: 0.00Peers compared: 261
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $4.99M, lower than 95% of all stocks globallySignificant
Market cap (USD): 4,987,230.904Global P5: 269,387,740.27
Revenue is $0, lower than 95% of all stocks globallySignificant
Revenue (USD): 0.00Global P5: 30,274,777.221
Companies that share the same coordination system — how they create, deliver, or capture value.
TheracryF PLC
Tier 1ProductionApproval-Gated PipelineRule
Purple Biotech Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
XTL Biopharmaceuticals Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Sulzer Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Thalia Therapeutics Plc
Tier 1ProductionApproval-Gated PipelineRule
Futura Medical plc
Tier 1ProductionApproval-Gated PipelineRule
Sailong Pharmaceutical Group Inc.
Tier 1ProductionApproval-Gated PipelineRule
Crism Therapeutics Corporation
Tier 1ProductionApproval-Gated PipelineRuleRisk
Cizzle Biotechnology Holdings Plc
Tier 1ProductionApproval-Gated PipelineRule
Roquefort Therapeutics plc
Tier 1ProductionApproval-Gated PipelineRuleRisk
Companies that share active interpretations — structural patterns currently present in both stocks.
Bakkt Holdings, Inc.
2 interpretationsGoodwill-Heavy EquityUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
Energypathways Plc
2 interpretationsGoodwill-Heavy EquityUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
Anemoi International Ltd.
2 interpretationsGoodwill-Heavy EquityUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated